Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

Abstract Hepatocellular carcinoma (HCC) is the second deadliest cancer worldwide, due to its high incidence and poor prognosis. Frequent initial presentation at advanced stages along with impaired liver function limit the use of a broad therapeutic arsenal in patients with HCC. Although main HCC onc...

Bibliografske podrobnosti
Main Authors:	Marc Hilmi, Cindy Neuzillet, Julien Calderaro, Fouad Lafdil, Jean-Michel Pawlotsky, Benoit Rousseau
Format:	Article
Jezik:	English
Izdano:	BMJ Publishing Group 2019-11-01
Serija:	Journal for ImmunoTherapy of Cancer
Teme:	Hepatocellular carcinoma Checkpoint inhibitor Drug combination Immunology Tumor microenvironment
Online dostop:	http://link.springer.com/article/10.1186/s40425-019-0824-5

Podobne knjige/članki

The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
od: Patrizia Leone, et al.
Izdano: (2021-05-01)

Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
od: Zeynep Akbulut, et al.
Izdano: (2024-04-01)

Research Progress on Immune Checkpoint Inhibitors in Treatment of Hepatocellular Carcinoma
od: CAO Jiali, et al.
Izdano: (2023-05-01)

Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle
od: Caecilia Sukowati, et al.
Izdano: (2022-09-01)

Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
od: Tong Liu, et al.
Izdano: (2024-08-01)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
od: Qingqing Xie, et al.
Izdano: (2022-09-01)

A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review
od: Faezeh Sharafi, et al.
Izdano: (2022-08-01)

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
od: Vito Longo, et al.
Izdano: (2019-10-01)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
od: Yue Chen, et al.
Izdano: (2022-06-01)

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
od: Sijia Ren, et al.
Izdano: (2021-06-01)

Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials
od: Jiahui Yu, et al.
Izdano: (2023-08-01)

Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma
od: Ying Xu, et al.
Izdano: (2021-01-01)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
od: Hongyu Pan, et al.
Izdano: (2025-03-01)

Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)
od: Xiufeng Liu, et al.
Izdano: (2024-01-01)

Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
od: Jin Zhang, et al.
Izdano: (2023-03-01)

Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments
od: Raufi A, et al.
Izdano: (2017-02-01)

Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints
od: Xiaoqiang Wang, et al.
Izdano: (2023-04-01)

Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection
od: Magnus Rizell, et al.
Izdano: (2020-04-01)

Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody
od: Masahiro Morita, et al.
Izdano: (2021-06-01)

Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: A systematic review and meta analysis
od: Yu Zhong, et al.
Izdano: (2022-08-01)

Bibliometric analysis of immune checkpoint inhibitors to treat hepatocellular carcinoma in patients with liver transplantation
od: Yanjiao Ou, et al.
Izdano: (2025-01-01)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
od: Francesco Tovoli, et al.
Izdano: (2020-10-01)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
od: Samantha M. Ruff, et al.
Izdano: (2023-06-01)

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors
od: Zihui Li, et al.
Izdano: (2020-11-01)

Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma
od: Alexander H. Shannon, et al.
Izdano: (2023-07-01)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
od: Yun Hua Lee, et al.
Izdano: (2020-09-01)

Immune checkpoint inhibitors for hepatocellular carcinoma – A game changer in treatment landscape
od: Tsung-Hao Liu, et al.
Izdano: (2022-08-01)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
od: Diederick J. van Doorn, et al.
Izdano: (2020-12-01)

Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
od: Deng L, et al.
Izdano: (2024-01-01)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
od: Ji Won Han, et al.
Izdano: (2021-09-01)

The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
od: Hsu HM, et al.
Izdano: (2023-10-01)

Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma
od: Raphael Mohr, et al.
Izdano: (2021-03-01)

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors
od: Lin Zhang, et al.
Izdano: (2022-08-01)

Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma
od: Masatoshi Kudo
Izdano: (2024-04-01)

Research status and progress of mechanism of T cell immune metabolism and its application combined with immune checkpoint inhibitor
od: LI Wei, ZHANG Shanling, TAO Yingjie, WANG Xudong
Izdano: (2021-07-01)

Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma
od: Alessandro Rizzo, et al.
Izdano: (2021-01-01)

Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
od: Ran Qin, et al.
Izdano: (2023-12-01)

An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma
od: Shen YC, et al.
Izdano: (2021-07-01)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
od: Huang JT, et al.
Izdano: (2022-11-01)

Modern cancer therapy: cryoablation meets immune checkpoint blockade
od: Qi Liu, et al.
Izdano: (2024-02-01)